Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

Healthcare Cannabis
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

InMed Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(3)
•••
Post by qwayludeon May 08, 2019 1:04pm
116 Views
Post# 29725075

InMed Pharmaceuticals to Report Third Quarter Fiscal 2019

InMed Pharmaceuticals to Report Third Quarter Fiscal 2019

VANCOUVER, BC, May 8, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended March 31, 2019, which is the Company's third quarter of fiscal year 2019 ("3Q19"), on Wednesday, May 15, 2019.

Conference Call & Webcast:

Wednesday, May 15, 2019 at 10:00 AM Pacific Time, 1:00 PM Eastern Time

Toronto:

+1.416.764.8688

Vancouver: 

+1.778.383.7413

North America (Toll Free):

+1.888.390.0546

Conference ID:

17193517

Webcast:  https://event.on24.com/wcc/r/1999675/955779A89027D040E64A5A3804E51DBE

Read more at https://stockhouse.com/news/press-releases/2019/05/08/inmed-pharmaceuticals-to-report-third-quarter-fiscal-2019-financial-results-and#X6isFKczTqjW3C54.99
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities